Core Viewpoint - WuXi XDC is expected to experience significant revenue and profit growth in 2025, driven by a record number of new projects and an acquisition aimed at enhancing production capacity [1][2][3][4] Group 1: Financial Performance - WuXi XDC anticipates a revenue increase of at least 45% YoY and net profit growth of over 38% YoY for 2025 [1] - Adjusted net profit before interest income and expenses is projected to rise by more than 45% YoY, and over 65% YoY when excluding foreign exchange impacts [1] - Revenue growth forecasts for 2025E, 2026E, and 2027E are 45.7%, 36.6%, and 31.7% YoY, respectively, with adjusted net income growth of 34.9%, 38.4%, and 32.9% YoY for the same years [4] Group 2: Project Developments - In 2025, WuXi XDC signed a record-high 70 new integrated projects, marking a 32% YoY increase [2] - Among these projects, 22 were transferred from external parties, indicating growing client trust [2] - The company reported a 125% YoY increase in PPQ-stage contracts, reaching 18, which suggests strong potential for commercial manufacturing [2] Group 3: Acquisition Strategy - WuXi XDC plans to acquire at least 60% interest in BioDlink through a cash tender offer at HK$4.00 per share, representing a 99% premium over the last closing price [3] - The acquisition aims to enhance WuXi XDC's drug production capacity, particularly for ADC DS and DP, which are currently in short supply [3] - BioDlink's facilities include two mAb facilities with capacities of 500–2,000L/batch and three DS facilities capable of producing over 800kg ADC DS annually [3]

Company Overview - VERAXA Biotech AG is an emerging leader in designing novel cancer therapies and is the proposed de-SPAC acquisition target of Voyager Acquisition Corp [1][4] - The company focuses on next-generation antibody-based therapeutics, including bispecific antibody-drug conjugates (ADCs) and T-cell engagers, utilizing transformative technologies [3] Leadership Appointment - Rick Austin, Ph.D., has been appointed as Chief Scientific Officer, effective May 1st, bringing over 25 years of experience in oncology discovery and early development [1][2] - Dr. Austin's previous roles include Vice President of Research at Harpoon Therapeutics and various positions at Amgen, where he led tumor immunology projects [2] Strategic Goals - The appointment of Dr. Austin is seen as pivotal for advancing VERAXA's BiTAC platform and clinical-stage pipeline, aiming to enhance the therapeutic window of cancer treatments while minimizing off-tumor toxicity [2][3] - The company is committed to tapping into the U.S. biopharma talent pool and expanding its scientific footprint [2] Business Combination - On April 22, 2025, VERAXA entered into a definitive business combination agreement with Voyager Acquisition Corp, which will lead to VERAXA becoming a publicly traded company on NASDAQ upon closing [4]